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Background: The inferior vena cava (IVC) diameter and degree of inspiratory collapse are 
used as echocardiographic indices in the estimation of right atrial pressure. Brain-natriuretic 
peptides (BNPs) are established biomarkers of myocardial wall stress. There is no informa-
tion available regarding the association between the IVC diameter and BNPs in patients with 
heart failure and various degrees of systolic performance. The purpose of this investigation 
is to quantify the degree to which natriuretic peptides (BNP and N-terminal pro-B natriuretic 
peptide [NT-ProBNP]) and echocardiographic-derived indices of right atrial pressure correlate 
in this patient population.
Methods: We examined 77 patients (mean age 61 ± 17 years, 44% male) with decompensated 
heart failure who underwent transthoracic echocardiography and, within a timeframe of 24 hours, 
determination of BNP and NT-ProBNP levels in venous blood. BNP and NT-ProBNP were 
analyzed after log transformation. The degree of association was measured by the correlation 
coefficient using the Pearson’s method.
Results: The mean ejection fraction was 50% ± 20%, and 33% of the study cohort had a 
remote history of heart failure. The mean IVC diameter was 1.85 cm ± 0.5, the mean BNP was 
274 pg/mL, the confidence interval (CI) was 95% (95% CI: 197–382), and the mean NT-ProBNP 
was 1994 pg/mL (95% CI: 1331–2989). There was a positive, albeit small, association between 
IVC diameter and BNP (r = 0.24, 95% CI: 0.01–0.44; P = 0.03) and NT-ProBNP (r = 0.27, 95% 
CI: 0.05–0.47; P = 0.01). Among patients with different degrees of IVC collapse in response 
to inspiration, values for BNP and NT-ProBNP did not differ substantially (P = 0.36 and 0.46 
for BNP and NT-ProBNP, respectively).
Conclusion: Natriuretic peptides correlate weakly with IVC size and do not predict changes 
in response to intrathoracic pressure.
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Background
Congestive heart failure is a leading cause of morbidity and mortality worldwide.1 
In the USA, over 1,000,000 patients are admitted each year with this diagnosis and 
5,000,000 live with the disease, at a cost of 27.9 billion dollars, which represents the 
costliest Medicare expenditure.2,3
Accurate estimation of volume status is of paramount importance in the manage-
ment of acutely decompensated heart failure (ADHF), as patients with elevated filling 
pressures prior to discharge have higher rehospitalization rates.4 Physical examination 
is inaccurate in estimating filling pressures, and invasive hemodynamic monitoring is 
infrequently used in the management of patients with ADHF.5,6
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Brain natriuretic peptides (BNPs) and echocardiography 
are commonly used in clinical practice to assess patients 
with ADHF. BNP and its precursor, N-terminal pro-B 
natriuretic peptide (NT-ProBNP), are released in response 
to myocardial wall stress and correlate well with pulmonary 
capillary pressure.7,8 Echocardiography provides informa-
tion regarding systolic and diastolic properties, left- and 
right-sided filling pressures, pulmonary artery pressure, and 
cardiac output.9
The purpose of this investigation was to quantify the 
degree to which natriuretic peptides (BNP and NT-ProBNP) 
and echocardiographic-derived indices of right atrial pressure 
correlate in patients with ADHF.
Methods
Patients
Eligible patients were retrospectively identified from our 
cardiac biomarker and echocardiography electronic databases 
using unique patient identifiers.
Inclusion criteria
Patients were eligible for participation in the study if they 
underwent echocardiographic and biomarker evaluation 
within 24 hours of each other for the management and/or 
diagnosis of heart failure at the University of Minnesota 
Medical Center during the study period from June 1 to 
December 1, 2006. The setting in which patients underwent 
echocardiography and biomarker evaluation was the coronary 
care or telemetry unit (88%), or the emergency department 
(12%). For inpatients with more than one biomarker and/or 
echocardiogram assessment during the index admission, only 
the one performed within 48 hours of hospital admission was 
considered for the study.
Exclusion criteria
Patients with severe left ventricular systolic dysfunction 
(ejection fraction [EF] ,35%), left ventricular assist devices, 
and transplant recipients were excluded. Patients with acute 
coronary syndromes or receiving positive pressure ventila-
tion or inotropic agents were also excluded. The study was 
approved by the Institutional Review Board and Ethics Com-
mittee at the University of Minnesota.
Echocardiography and biomarkers
Echocardiography was performed by trained sonographers 
using a transthoracic approach in the standard parasternal, 
apical, and subcostal views. Two investigators blinded to bio-
marker levels reviewed all echocardiograms. Cardiac chamber 
dimensions were estimated from the parasternal long-axis view 
using two-dimensional (2D)-guided linear measurements, as 
recommended by the American Society of Echocardiography 
(ASE).10 Right ventricular (RV) function was qualitatively 
assessed after integration of multiple views, as recommended 
by the ASE. The main criterion used to assess RV function was 
the degree of tricuspid annulus displacement toward the apex 
in systole (normal displacement is 1.5–2 cm).10 RV systolic 
pressure was determined by measuring the peak velocity of 
the tricuspid regurgitation jet using multiple views. Inferior 
vena cava (IVC) dimension was measured from a subcostal 
view 1 cm from the junction between the IVC and the right 
atrium during quiet respiration (Figure 1). Changes in IVC 
dimension in response to respiration were described as col-
lapse $ 50% or ,50%, or no change. The NT-ProBNP and 
BNP levels were measured using commercially available 
immunoassays (Elecsys proBNP; Roche Diagnostics, Basel, 
Switzerland and Triage BNP Test; Biosite Diagnostics, San 
Diego, CA, respectively).
Statistical analysis
The baseline characteristics of study patients are presented as 
percentages for dichotomous variables and mean ± standard 
deviation (SD), or median ± with interquartile ranges for 
continuous variables, as appropriate. BNP and NT-ProBNP 
values were analyzed after log transformation. The degree of 
association between IVC size and biomarkers was measured 
by the correlation coefficient using the Pearson’s method 
and depicted in scatter plots. Analysis of variance was used 
Figure 1 Examination of the inferior vena cava (IVC) in the subcostal long-axis view 
1 cm from the right atria-inferior vena cava junction.
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to perform comparisons across the three groups of IVC 
  collapse. Interobserver agreement between the two readers 
was assessed in 20 patients using the κ statistic, an index 
that compares agreement against what might be expected 
by chance. Possible values range from 1 (perfect agreement) 
via 0 (no agreement above that expected by chance) to -1 
(complete disagreement). The software programs SPSS 
  (version 11.0; SPSS Inc, Chicago, IL) and MedCalc for 
Windows (version 9.5.0.0; MedCalc Software, Mariakerke, 
Belgium) were used for data analysis.
Results
Baseline characteristics
The mean age (±SD) of the study group was 61 ± 17 years 
and 44% were male. A third of the group had a remote history 
of congestive heart failure or coronary artery disease.
At presentation, 57% had worsening dyspnea (functional 
class III–IV), and virtually all patients (99%) showed one 
or more physical signs of decompensated heart failure upon 
examination. These included crackles (17%), lower extremity 
edema (49%), third heart sound (S3) (3.5%), and elevation 
in jugular venous pressure (30%).
The mean ejection fraction, end-systolic dimension, and 
left atria size were 50% ± 20%, 34 ± 13 mm, and 43 ± 9 mm, 
respectively. Background medical therapies at the time of 
presentation included beta-blockers (54%), diuretics (64%), 
angiotensin-converting enzyme inhibitors or angiotensin 
receptor blockers (35%). Other baseline clinical, labora-
tory, and echocardiographic characteristics are described in 
Tables 1 and 2.
Inferior vena cava and biomarker 
assessment
Interobserver agreement for IVC size and collapsibility 
  measurements was very good (κ = 0.85 and 0.88, respectively). 
The mean IVC diameter was 1.85 ± 0.5 cm, the mean BNP 
was 274 pg/mL (95% CI: 197–382), and the mean NT-
ProBNP was 1994 pg/mL (95% CI: 1331–2989). There 
was a positive correlation between IVC diameter and both 
BNP and pro-BNP. The correlation coefficient for BNP, as 
it relates to IVC diameter (Figure 2), was 0.24 (95% CI: 
0.01–0.44; P = 0.03). The correlation coefficient for NT-
ProBNP and IVC diameter (Figure 3) was 0.27 (95% CI: 
0.05–0.47; P = 0.01).
Subgroup analysis stratified by sex showed a more robust 
association between natriuretic peptides and IVC size among 
men (correlation coefficient for BNP was 0.33, P = 0.05; and 
for NT-proBNP it was 0.36; P = 0.03) when compared to 
women (correlation coefficient for BNP was 0.14, P = 0.35; 
and for NT-proBNP it was 0.17; P = 0.27).
Values for BNP and NT-ProBNP overlapped sub-
stantially across different IVC collapsibility subgroups 
(  Figure 4A and B; P = 0.36 and 0.46 for BNP and 
NT-ProBNP, respectively). In contrast, baseline IVC 
diameter correlated well with variations in IVC size in 
response to changes in   intrathoracic pressure (correlation 
  coefficient = 0.46, P , 0.001; Figure 5).
Table 1 Baseline characteristics of the study cohort (n = 77)
Demographics
Age (years) (±SD) 61 ± 17
Male (%) 44%
Caucasian (%) 70%
Medical history
Diabetes (%) 30%
Arterial hypertension (%) 57%
Hyperlipidemia (%) 37%
Coronary artery disease (%) 30%
Prior heart failure (%) 33%
Baseline clinical and laboratory data
Inpatient (%) 88%
Systolic blood pressure (mmHg) (±SD) 127 (±23)
Diastolic blood pressure (mmHg) (±SD) 75 (±13)
Heart rate (bpm) (±SD) 84 (±17)
Creatinine clearance (mL/min/m2) ±SD 51 ± 20
Mean brain natriuretic peptide (95% CI) pg/mL 274 (197–382)
Mean N-terminal pro-brain natriuretic peptide  
(95% CI) pg/mL
1994 (1331–2989)
Serum sodium mEq/L (±SD) 138 (±5)
Serum potassium mEq/L (±SD) 4.6 (±5)
Hemoglobin mg/dL (±SD) 11.3 (±2)
Abbreviations: CI, confidence interval; SD, standard deviation; bpm, beats per 
minute.
Table 2 Echocardiographic characteristics of study patients (n = 77)
End-diastolic dimension (mm) ±SD 49 ± 11
End-systolic dimension (mm) ±SD 34 ± 13
Ejection fraction (%) ±SD 50 ± 20
Left atrial size (mm) 43 ± 9
Inferior vena cava size (cm) ±SD 1.8 ± 0.5
Right ventricular systolic pressure (mmHg) ±SD 41 ± 16
Right ventricular function (%)
Normal 74%
Mildly reduced 9%
Moderately reduced 13%
Severely reduced 1%
Unable to assess 3%
Respiratory collapse of the inferior vena cava
,50% 35%
$50% 34%
Absent 31%
Abbreviation: SD, standard deviation.
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Discussion
In this cohort of patients with acute heart failure and preserved 
or mildly reduced systolic function, we found a positive asso-
ciation between the natriuretic peptides BNP and NT-ProBNP, 
and IVC size. In contrast, neither BNP nor NT-ProBNP showed 
a good correlation with the response of the IVC to changes in 
intrathoracic pressure. Using the 100r² formula, which is the 
percentage of the variability of the data that is explained by 
the association of the two variables, it can be concluded that 
biomarkers explain less than 10% of the variability in IVC 
dimensions without major differences between BNP and NT-
ProBNP.10 The results of this study suggest that commonly used 
indices of right atrial pressure (IVC size and response to respi-
ration) and left ventricular end-diastolic pressure (natriuretic 
peptides) complement each other by providing information 
about filling pressures in both heart chambers.
Among patients with systolic heart failure, BNP has 
been shown to correlate with IVC size.11 The magnitude 
of this association was stronger with systolic heart failure 
patients than in our study of patients with preserved or 
mildly reduced ejection fraction. This phenomenon, whereby 
echocardiography-derived indices of filling pressures 
perform better among patients with systolic dysfunction, 
has been reported previously for E/e’ and other indices of 
pulmonary capillary pressure.12 Alternatively, patients with 
better preserved EF may not have as much elevation in right 
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Figure 2 Scatter plot of log-transformed brain natriuretic peptide (BNP) and inferior vena cava size (IVC).
Notes: Correlation coefficient r = 0.24, confidence interval (CI): 0.01–0.44; P = 0.03.
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Figure 3 Scatter plot of log-transformed N-terminal pro-brain natriuretic peptide (NT-ProBNP) and inferior vena cava size (IVC).
Notes: Correlation coefficient r = 0.27, confidence interval (CI): 0.05–0.47; P = 0.01.
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atrial pressure as those with systolic heart failure, despite the 
presence of RV diastolic dysfunction.13
The finding of a lack of correlation between natriuretic 
peptides and IVC among women is interesting, although 
caution is advised when interpreting this finding due to the 
small sample size (type II statistical error). This finding needs 
to be confirmed in larger studies.
The mechanism underlying increased natriuretic peptides 
in females is unclear, although Redfield et al reported 21% 
higher BNP levels in women taking hormone replacement 
therapy, which may suggest that estrogens play a role in the 
increased levels.14
The IVC is a compliant intra-abdominal vessel that 
changes in diameter in response to fluctuations in right atrial 
pressure and volume overload.15 As shown in our study, the 
degree of IVC collapse in response to intrathoracic pressure 
correlates with baseline IVC diameter, and when used in 
conjunction with IVC size provides an accurate, noninva-
sive estimation of right atrial pressure.16 A rapid assessment 
of IVC physiology could be performed at the bedside by a 
noncardiologist and also in the emergency department for 
patients with unexplained dyspnea.17,18
BNP and NT-ProBNP are useful in the diagnosis of ADHF 
and provide independent prognostic information that allows 
optimization of medical therapies.7,8,19,20 Both natriuretic 
peptides and echocardiography are routinely used in the 
management of patients with decompensated heart failure.21 
Our data suggests that natriuretic peptides and echocardiog-
raphy provide complementary data with regard to the status 
of right- and left-sided filling pressures.
Limitations
Our study has several limitations intrinsic to this type of study 
design (retrospective chart review). First, invasive hemody-
namic measurement was not routinely applied in our study 
population. Second, the majority of the patients included 
in the study were hospitalized with decompensated heart 
failure at the time of the study. Therefore, the association 
between natriuretic peptides and IVC dimension described 
may not apply to an outpatient, compensated heart failure 
cohort. Third, we did not perform serial IVC or biomarker 
measurements, nor did we collect information regarding 
medication administration that could potentially influence 
both natriuretic peptides and IVC size (ie, diuretics) during 
the index admission. Therefore, we are unable to comment on 
any dynamic changes that may occur between IVC size and 
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Figure 4 Scatter plot of log-transformed values of (A) N-terminal pro-brain natriuretic peptide (NT-ProBNP) and (B) brain natriuretic peptide (BNP) (Y axis) according to 
respirophasic changes in the inferior vena cava (IVC) size (X axis) (P = 0.46 and 0.36 for NT-ProBNP and BNP, respectively).
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Figure 5 Scatter plot showing the relationship between inferior vena cava (IVC) size, 
cm, and the degree of IVC inspiratory collapse (analysis of variance P , 0.001).
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
217
Biomarkers and echocardiographyVascular Health and Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/vascular-health-and-risk-management-journal
Vascular Health and Risk Management is an international, peer-
reviewed journal of therapeutics and risk management, focusing on 
concise rapid reporting of clinical studies on the processes involved 
in the maintenance of vascular health; the monitoring, prevention and 
treatment of vascular disease and its sequelae; and the involvement of 
metabolic disorders, particularly diabetes. This journal is indexed on 
PubMed Central and MedLine. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Vascular Health and Risk Management 2012:8
natriuretic peptides during the treatment of ADHF. Finally, 
elevation in natriuretic peptides is not solely a reflection of 
cardiac filling pressures.22,23 Factors known to have an impact 
on natriuretic peptides, such as age, sex, creatinine clearance, 
and body mass index, could have influenced our results and 
may explain the weak correlation between natriuretic pep-
tides and IVC size and collapsibility.
Conclusion
Among patients with acutely decompensated heart failure, 
natriuretic peptides correlate weakly with IVC size and do 
not predict changes in response to intrathoracic pressure. 
These data suggest a complementary role for right-sided 
echocardiography and biomarker evaluation.
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